The FDA will review a supplemental NDA from Pfizer (PFE) and Bristol-Myers Squibb (BMY) to...


The FDA will review a supplemental NDA from Pfizer (PFE) and Bristol-Myers Squibb (BMY) to expand the use of their Eliquis blood thinner to help prevent deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery. The review follows a successful trial for this purpose. The FDA's deadline to decide is March 15, 2014. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs